LETTER FROM THE CEO & BOARD PRESIDENT

In 2022, we had a laser-sharp focus on one thing: to enable patients in need to gain access to high-impact medicines in resource-challenged countries. In pursuit of that goal, we forged deep partnerships, provided access to innovative treatments, expanded diagnostic testing, brought data-driven rigor to our internal systems, and launched programs designed to help patients overcome barriers to access.

By the end of 2022 more than 34,000 patients in over 75 of the most resource-constrained countries had received treatment and care, free of cost.

While satisfying and deeply humbling, we know there is much work to be done. Our Equity in Action strategic plan, launched in 2021, provided a clear roadmap to accelerate health equity for patients in need around the world.

This renewed commitment focused us on three priorities that drove our efforts throughout last year, our 25th anniversary year. So, how did we do in 2022?

1. TREAT MORE PATIENTS

We are happy to say we reached an additional 3,000 newly diagnosed patients—that is 3,000 families who can smile a little easier now. Our treatment access programs reached patients in Laos and Guinea for the first time, bringing the number of countries where we support patients to 77, and, importantly, grew our Social Determinants of Health programs by 38%, helping patients overcome barriers to treatment access such as transportation costs. In a world of impersonal online interactions, our teams stayed true to our unwavering patient focus through more than 52,000 unique one-on-one personal interactions with patients and caregivers in 2022.

2. AMPLIFY OUR VOICE

Pat accepted the role of chairing the Access to Oncology Medicines (ATOM) council, a union for the International Cancer Control coalition comprised of deeply committed organizations and individuals intent on accelerating access to cancer treatment. This offers a great opportunity for us to make the patient voices heard by leveraging the combined resources of the council.

3. SUSTAIN OUR WORK

To sustain our momentum, we strengthened our staff in regions and functions where the needs are most critical. Their innate cultural understanding and enthusiasm never fail to amaze. Our continued strength and impact depend on our sustained partnerships. Reflecting this, we launched the Humanitarian Partnership for Access to Critical Treatment (Humanitarian PACT) for Advanced Breast Cancer. With breast cancer still the leading cause of death for women worldwide, this is not just an exciting first for us, but also an important step forward for women in low-resource settings.

In closing, we have a clear mission, a core set of beliefs to guide our actions, and a measurable plan to take us forward. Our patients keep us inspired and motivated. Our supporters, donors, and friends provide the wind to our sails. We have never been more confident in our ability to accelerate health equity in collaboration with our partners for the many thousands in need who are waiting. We share this annual report to update you on our progress and ask for your continued support.

With sincere gratitude and hope for the future,

PAT GARCIA-GONZALEZ
CEO and Co-Founder

PAULA BOUNTBEE
Board President

TABLE OF CONTENTS

| 2022 BY THE NUMBERS | 02 |
| TREAT          | 06 |
| AMPLIFY        | 08 |
| SUSTAIN        | 10 |
| FINANCIALS     | 12 |
| DONORS         | 13 |

OUR MISSION

Our mission is to accelerate health equity. We do this by delivering medication, technology, and services to patients facing cancer and other critical illnesses, focusing our energy on those whom no one else is helping.

OUR VISION

Our vision is a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and hope.
2022
BY THE NUMBERS

380
partner medical institutions

9M+
daily doses of life extending cancer and rare disease medication delivered

91%
of patients supported, continuing from previous years

77
low- and middle-income countries supported

8,890
molecular diagnostic tests administered

73
global team members serving patients

327
treatment shipments delivered through our supply chain

52K
number of one-to-one contacts by our team with patients

505/partner healthcare professionals

15/countries receiving access to new treatments

3,072
patients reaching treatment for the first time

34,131
total number of patients with cancer and critical diseases receiving access to treatment

29,829
patients treated for Chronic Myeloid Leukemia (CML)

3,124
patients treated for Gastrointestinal Stromal Tumors (GIST)

529
patients treated for Renal Cell Carcinoma (RCC)

375
patients treated for Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)

143
patients treated for Dermatofibrosarcoma Protuberans (DFSP)

71
patients treated for ALK- and ROS1-positive non-small cell Lung Cancer (ALK+ & ROS1+ NSCLC)

34,131
total number of patients with cancer and critical diseases receiving access to treatment

6
patients treated for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

3
patients treated for Primitive NeuroEctodermal Tumors (pNET)

40
patients treated for Hypereosinophilic syndrome/Chronic Eosinophilic Leukemia (HES/CEL)

9
patients treated for Myelodysplastic Syndromes/Myeloproliferative Disorders (MDS/MPD)

2
patients treated for Systemic Mastocytosis (SM)
We expanded our access programs beyond cancer for the first time, piloting a new program for Transthyretin Amyloid Cardiomyopathy (ATTR-CM), an ultra-rare disease.

Supporters across the globe came together to celebrate the 25th anniversary of The Max Foundation raising $264,000 to help accelerate equal access to treatment.

We provided nearly 9,000 diagnostic tests, 48% more than the prior year, recognizing the importance of diagnosis and treatment monitoring.

We grew our support to help patients overcome barriers by 38%, expanding initiatives for transportation to treatment centers, tuition grants to keep children of cancer patients in schools, patient meetings to support and educate, and direct assistance via our helpline.

We launched the Humanitarian PACT for Advanced Breast Cancer to increase global access to treatment, care, and support for women living with advanced breast cancer.

We expanded geographically to provide targeted access where there is none today, opening a treatment access program in Laos and Guinea in December, making significant progress on our core strategic goal.

**Dr. Yangchen from Bhutan**

“I've seen that Max looks beyond just donations alone. Because a donation, while it is beneficial for a resource-constrained country like Bhutan, we are looking forward to future collaborations in terms of how Max has been helping other countries in terms of training the manpower, giving access to reagents, testing equipment. So, we look forward to a greater and much more fruitful collaboration in the future. Thank you so much for helping people all over the world. It is an inspiring and noble job that you are doing.”
TREAT MORE PATIENTS

PROGRESS ON OUR PRIORITIES

We increased patient access to treatment significantly in 2022 in parts of the world that need them the most. More than 3,000 newly diagnosed patients received treatment at no cost across Africa, the Middle East, Eastern Europe, Central Asia, Latin America, and Southeast Asia. We expanded our presence to include Laos and Guinea for the first time, bringing our geographic network to 77 countries with 380 institutions and 505 physicians collaborating with us to help patients.

Studies suggest that conditions in which people are born, grow, work, live, and age, along with the forces that govern their lives, could be significant influencers on their health outcomes. These factors – termed Social Determinants of Health (SDoH) – can be powerful barriers to treatment. In 2022, patient assistance through our five SDoH programs, designed to help patients overcome these barriers, increased by 38%, reaching more than 3,200 people. Our teams logged more than 52,000 unique one-on-one interactions with patients and caregivers throughout the year. We opened a new SDoH program in three new countries, bringing our SDoH patient reach to 16 countries.

Accurate diagnosis and monitoring remains a significant barrier for patients in low-resource countries. Worldwide, we increased our critical diagnostics support by 48% in tests delivered and by 86% in the use of Spot On CML tests through our collaboration with Radich Lab at Fred Hutch Cancer Center.

PATIENT PERSPECTIVE

“Although some discouraged me from taking on treatment, I am happy that I did and encourage others to take on the treatment and experience first-hand a life-altering journey with the opportunity that The Max Foundation provides.”

Joanne from Papua New Guinea

Joanne and her family. Joanne is now in stable health after being provided with medicines. She says she realizes the “importance of treatment and how it has positively impacted my life.”
PATIENT PERSPECTIVE

“I can’t find the appropriate words in vocabulary to express my feelings for Max! Imagine someone helping you from far away and you don’t even know his/her name, you don’t know who he/she is to thank for, he/she continues to support for years, and you continue your life – this is something incredible.”

Murad from Armenia

PROGRESS ON OUR PRIORITIES

Externally and internally, we advanced closer to our goal of continuing to amplify our patients’ voices. Externally, Pat assumed chairmanship for Access to Oncology Medicines Coalition (ATOM) Council, a global partnership sponsored by the Union for International Cancer Control, that brings together 40 leading organizations with the single shared goal of improving access to essential cancer medicines in lower-to-middle income countries.

Internally, we launched a new communications department headed by a Vice President designed notably to solidify our organizational outreach, strengthen our presence across key channels, and provide a consistent voice to our multiple stakeholders as we move beyond access to medicine to include Health Systems Strengthening and Social Determinants of Health (SDoH) initiatives.

Murad (second from left), a father of three daughters, who has been on treatment for leukemia for 19 years says, “I think life is a fairy tale. I believe in wonders and amazements.”
Looking ahead to building and sustaining our momentum, we grew the strength of our organization through selective hires in much-needed regions and functions. Our diverse global team are conversant in nearly 40 languages, giving them unique local cultural relevance, strength, and influence to help advance patient needs at the country level.

Reflecting our approach to accelerating health equity through strategic partnerships, we launched Humanitarian Partnership for Access to Critical Treatment (Humanitarian PACT) to provide access to treatment for HR positive/HER2 negative advanced breast cancer patients. Founding partners of the Humanitarian PACT for Advanced Breast Cancer include the ABC Global Alliance, the American Society for Clinical Pathology, Cepheid, and Novartis AG. This innovative collaboration is grounded in a shared commitment to increase global access to treatment for people living with cancer.

**PHYSICIAN PERSPECTIVE**

“In 1997, I entered the medical faculty of the Azerbaijan Medical University and have participated in writing a guideline for patients with leukemia and currently involved in writing a Guideline on Treatment of Follicular Lymphoma for physicians. I have also run patient education for leukemia patients several times. I want to thank The Max Foundation for giving me the chance to work with innovative medicines, to give incurable patients a chance to survive, to give hope and equity in health.”

Dr. Abbasova, physician from Azerbaijan

“Becoming a doctor is not only about diagnosing correctly or prescribing effective medicine for treatment; it is about healing by understanding, talking, making patients feel strong and recovering”.

- Dr. Oksana Abbasova
# REVENUE & EXPENSES
## FOR THE YEAR ENDING JUNE 30, 2022

## REVENUE

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>In-kind pharmaceutical contributions*</td>
<td>$307,241,383</td>
</tr>
<tr>
<td>Contributions, grants, &amp; sponsorships</td>
<td>$11,539,837</td>
</tr>
<tr>
<td>Diagnostic program revenue</td>
<td>$317,805</td>
</tr>
<tr>
<td>Other Income</td>
<td>$4,252</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$319,103,277</strong></td>
</tr>
</tbody>
</table>

## EXPENSES

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program expenses</td>
<td>$7,844,916</td>
</tr>
<tr>
<td>Program in-kind expenses</td>
<td>$365,352,278</td>
</tr>
<tr>
<td>Management &amp; general expenses</td>
<td>$1,861,527</td>
</tr>
<tr>
<td>Fundraising expenses</td>
<td>$691,527</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$375,750,248</strong></td>
</tr>
</tbody>
</table>

*The Organization recognizes in-kind contributions consisting of pharmaceuticals, medical devices, and related products. These goods are recorded as inventory and revenue at fair value at the time received and as a reduction to inventory and program expense when the goods are distributed. Pharmaceutical inventory is released using a specific identification method based on expiration date and is reviewed at least annually for impairment. Pharmaceutical inventory is disposed and written off as obsolete when it is determined the pharmaceutical cannot be imported into a specific country of destination with shelf-life sufficient to comply with local importation regulations and the Organization’s own guidelines.

## DONORS & SUPPORTERS

Your invaluable support allows people facing cancer around the world to live with dignity and hope. Without your generosity and support, we will not achieve our ambitious goals to reach more patients in need. Together, we can overcome inequities in health outcomes and provide the vital medicines to patients no matter where they live. Thank you for joining our mission to accelerate health equity.

### HUMANITARIAN PACT PARTNERS

- ABC Global Alliance
- American Society for Clinical Pathology
- Bristol Myers Squibb

### CORPORATE PARTNERS

- AA Pharmacy
- Armenian Missionary Association of America
- Auburn Rotary Club
- Bank of America
- BD
- Bellevue Breakfast Rotary Club
- Bellevue Rotary Club
- Bourne Capital Partners, LLC
- Bristol Myers Squibb Foundation
- Copiers Northwest
- F5
- Fearley
- Federal Way Rotary Club
- Fred Hutchinson Cancer Center
- GenePath Diagnostics
- GRAIL
- Heavyocity Music
- IHME
- Issaquah Rotary Club
- Kent Rotary Club
- Lake Union Rotary Club
- Mercier Island Rotary Club
- Occidental Lodge #72 F. & A.M.
- Redmond Rotary Club
- Roche
- Rotary District 5030
- Seagen
- Shoreline Rotary Club
- Suquamish Tribe
- Tanner Pharma Group

### INDIVIDUAL DONORS

- Oluymeni Ajayi
- Paul Aliu
- Benjamin & Tinya Anderson
- Alicia Annamalay
- Julian Atim
- Ellen Baker
- Ciandra Barber
- Liz Barrett
- Jerry P. Scott, CPA & Odette Batik
- Gregory Bell
- Cari & Greg Benn
- Matt & Kim Benson
- David Berg
- Terri-Ann Betancourt
- Dr. Beverly Mitchell
- Jossé & Nicole Blanco
- Aaron Blank
- Phil Boeder
- Stephanie Bohannan
- Nicole Bond Edwards
- Francis Bouchard
- Paul & Paula Boultebe
- Edward Briercheck
- Randall Broad
- Carol Choi
- Brent Christofferson
- Laura Cisar
- Viswa Colluru
- Wilma Comenat
- Christopher & Jamie Conner
- Liza & Geoffrey Cook
- Eric & Dipti Cox
- David Craig
INDIVIDUAL DONORS CONTINUED

Irina Datikashvili-David
Ted Davis
Sonia de Bary Pereda
Amadou Diarra
Drs. Jerald Radich & Dorcas Dobie
Talia Jaide Ni Dufaigh
Liz Dwyer
Rolando Valencia & Joyce Egonia
Patrick Flanagan
Frank R. Foresta Jr
Pat Garcia-Gonzalez
Cristin Gordon-Maclean
Sarah Casarella & George Gradwohl
Nancy Grande
Raiza Ramirez & Gabriel Guerrero
Sara Hamilton
Lutz Hegemann, MD, PhD
William Heisel
Pinky Herrera & John Hibbard
Tracey Higgins
Carter D. Hill
Mika Matsuzaki & Mako Hill
Lawrence N Shulman, MD
& Linda Jacobs PhD, NP
Julie Jenson
Patricia Jewell
Eric Johnson
Elaine Kapjian-Pitt
Karen M. Kasprzyk
Patricia Keegan
John Ketchum
Ken Kieffer
Andrew Kim
Ami King
Kevin King
Chris Korsmo
Steve Kradjian
Susan & Bob Kresoek
Nisith Kumar
Lindsay Kurs
Claire LeBuffe
Siew Gim Lee
Mark Leggett
Daniel Lieberman
Fausto Loberiza
Albert Lui
Andrew Lyon
Curt & Ana Malloy
Michael and Jennifer Mandola
Laura Barringer & Guy Maas
Bryan Murphy-Eustis
& Lauren Marcel
Brian Meenaghan
William Comenat
& Carol Ann Mejdrich
Arda Melkonian
Dan Milner
Nana Minkah
Kevin & Kathryn Mueller
Dr. Abd Razak Muhammad
Tara Mulcahy
Anne Murray
Mark & Joan Murray
Lana Narancic
Jeanne Neptune
Alexis Opree-Gradwohl
Erich Schwartz & Eric Ozretich
Rod Padua
Tiffany S. Patrick
Patricia Pearce
Mary Pendergast
Rob Keel & Anna Paola Pradal
Elizabeth Prescott, Ph.D.
Steve Price
Yinyu Quan
Gregory Radovich
Belinda Richardson
Jordan & Kate Rickard
Linda Rickard
Karla Robinson
Gilbert L Rodrigues
Dr. Carlos Rodriguez-Galindo
Abby Russo
Tony & Selene Russo
Jennifer & Nathan Rynning
Olga Sala-Torra
Raquel Sanchez
Amanda & Josh Sandoz
Arlene Saryan
Judith Saryan
Stephen & Andrea Scalia
Amanda Schwartz
James Sherpa
Maria Pia Ruffilli M.D.
& Susan Silbermann
Pamela Sires
Andrea Sparrey
Sierra Stayberg
Marina Taylor
Mark Taylor
Stanley Thomas
Andrea Towlerton
Dr. Irving Weissman
& Mike & Ann Tuskuamoto-Weissman
& Dr. Ann Tuskuamoto-Weissman
Viji & Krishnaswami Venkatesh
Adam Walkiewicz
Karen Wain
Mr. & Mrs. Joseph J. Ward
Edus & Linda Warren
Kathie Watson
Glen Weissman
Madeline Wettstein
Jeffrey Wilson
Murray & Vera Wilson
Sarah & Jason Wine
Mabel Woloj
William & Elizabeth Wrigglesworth
Andrielle Yost

LEADERSHIP

LEADERSHIP TEAM

Pat Garcia-Gonzalez
Chief Executive Officer
Wilma Comenat
Vice President, Development
Geoff Cook
Vice President, Communications
Inés García González
Region Head for Latin America

PAUL BOULTBEE
President of the Board

Pat Garcia-Gonzalez
Chief Executive Officer

Robert Farmer
Honorary Board Member

Susan Jerian, MD
Board Member, President
and Founder, ONCORD, Inc.

CURT MALLOY, JD, MPH
Treasurer of the Board,
Chief Operating Officer at Cancer
Research and Biostatistics (CRAB)

Mika Matsuzaki
Secretary of the Board,
Assistant Professor at Johns
Hopkins Bloomberg School of Public Health

HEMATOLOGY ADVISORS

Jorge E. Cortes, MD
Brian J. Druker, MD
Andres Hochhaus, MD
Timothy Hughes, MD

ONDHOLOGY ADVISORS

Fatima Cardoso, MD
Matias Chacon, MD
George D. Demetri, MD
Alexandru Emu, MD
Yehoda M. Martel, MD, MSCE

CARDIOLOGY ADVISOR

| Dr. Juan Pablo Costabel

CATHARINA SCHEEPERS
Region Head for Africa & Middle East

VIJI VENKATESH
Region Head for South Asia

J. MICHAEL WRIGGLESWORTH
Senior Director of Program Strategy & Data Solutions

BOARD OF DIRECTORS

PAULA BOUTLIEE
President of the Board

Michael J. Mauro, MD
Beverly Mitchell, MD
Javier Pinilla-Ibarz, MD, PhD
Jerald Radich, MD

CURT MALLOY, JD, MPH
Treasurer of the Board,
Chief Operating Officer at Cancer
Research and Biostatistics (CRAB)

Mika Matsuzaki
Secretary of the Board,
Assistant Professor at Johns
Hopkins Bloomberg School of Public Health

J. MICHAEL WRIGGLESWORTH
Senior Director of Program Strategy & Data Solutions

CATHARINA SCHEEPERS
Region Head for Africa & Middle East

VIJ I VENKATESH
Region Head for South Asia

J. MICHAEL WRIGGLESWORTH
Senior Director of Program Strategy & Data Solutions

MABEL WOLOJ
Board Member,
Principal at MW Consulting

PAUL BOULTBEE
President of the Board

Pat Garcia-Gonzalez
Chief Executive Officer

Robert Farmer
Honorary Board Member

Susan Jerian, MD
Board Member, President
and Founder, ONCORD, Inc.

CURT MALLOY, JD, MPH
Treasurer of the Board,
Chief Operating Officer at Cancer
Research and Biostatistics (CRAB)

Mika Matsuzaki
Secretary of the Board,
Assistant Professor at Johns
Hopkins Bloomberg School of Public Health

HEMATOLOGY ADVISORS

Jorge E. Cortes, MD
Brian J. Druker, MD
Andres Hochhaus, MD
Timothy Hughes, MD

ONDHOLOGY ADVISORS

Fatima Cardoso, MD
Matias Chacon, MD
George D. Demetri, MD
Alexandru Emu, MD
Yehoda M. Martel, MD, MSCE

CARDIOLOGY ADVISOR

| Dr. Juan Pablo Costabel
Yogiraj is a leukemia patient-advocate who is pictured here in Pune with Max team members. Along with his family, Yogiraj is highly active in providing support to other patients and organizing patient support group meetings. His favorite quote is “cancer didn’t bring me to my knees; it brought me to my feet.”

Yogiraj from Pune, India

PATIENT PERSPECTIVE

“It is almost 10 years now since I became part of the Max Family. I am amazed by the power of kindhearted words and emotional support. Sounds quite simple, but these two things can take down any barrier in your life. In our life, whenever we come across any difficulty, advice from experienced people plays a key role in overcoming that situation.”

Yogiraj from Pune, India